Clinical trials located in

Siena

Siena city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Siena, nestled in Italy’s Tuscany region, is renowned for its medieval brick buildings and the fan-shaped Piazza del Campo, the site of the famous Palio horse race held twice a year. The city’s 13th-century public square is dominated by the striking Gothic Palazzo Pubblico and its tower, Torre del Mangia. Siena’s historic center is a UNESCO World Heritage Site, a testament to its preserved Gothic architecture and significant cultural heritage. The city also houses the Siena Cathedral, an exquisite example of Italian Romanesque-Gothic architecture.

  • CT-EU-00117689

    Study ANV419 as monotherapy or in combination with pembrolizumab and ipilimumab in patients with metastatic melanoma

    The aim of this study is to test a new drug called ANV419. It will be given alone or in combination with other approved cancer medicines such as pembrolizumab or ipilimumab. The main goal is to see how well ANV419 works and whether it is safe for people with advanced cutaneous melanoma, which is a type of skin cancer that has spread or cannot be surgically removed.

    The trial is currently open to adult patients who have already been treated with drugs that target PD-1 or PD-L1 proteins, but whose cancer has continued to progress. The study will have different parts. First, doctors will find the right dose of ANV419 to use alone or in combination with other treatments. They will then check how many patients respond to treatment, which means their tumors shrink or stop spreading.

    • ANV419
    • Ipilimumab
    • Pembrolizumab
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study on Secukinumab for Rotator Cuff Tendinopathy

    This clinical trial evaluates the efficacy of the drug secukinumab in treating moderate to severe rotator cuff tendinopathy. Participants will receive secukinumab or a placebo, both in conjunction with standard care, to see if there is an improvement in symptoms and physical function. The research is conducted through a controlled setup where neither the participants nor the researchers know who receives the drug or the placebo to ensure unbiased results. This research aims to provide valuable insights into the potential benefits of secukinumab for those struggling with this shoulder condition.

    • placebo
    • Secukinumab
  • Clinical Trial for Finding the Best Dose of Clodronate for Painful Knee Osteoarthritis

    Howdy there, folks! This here clinical trial is aimin’ to find the best dose of a medicine called clodronate for treatin’ painful knee arthritis. It’s gonna be split into two parts.

    In the first part, they’ll have four groups of folks with knee arthritis. Three of them groups will get different doses of clodronate injected right into their knee once a week for four weeks. The fourth group will get a placebo, which is like a fake medicine. They’ll be keepin’ an eye on how safe and tolerable them different doses are.

    Once they figure out which dose works best without too many side effects, they’ll move on to the second part. In that part, they’ll have two groups – one gettin’ the best dose of clodronate from the first part, and the other gettin’ a placebo again. They’ll be checkin’ to see how effective and safe that best dose really is for helpin’ with knee arthritis pain.

    The main thing they’re lookin’ for is if the clodronate can reduce knee pain by at least 10 millimeters on a special pain scale called the Visual Analogue Scale, compared to the placebo group. They’ll be measurin’ that around 7 weeks into the study.

    So in a nutshell, they’re tryin’ to find the best and safest dose of clodronate for helpin’ folks with painful knee arthritis. It’s a two-part study, and they’ll be keepin’ a close eye on how well it works and how well it’s tolerated.

    • Clodronate
    • placebo
  • A study comparing biosimilar nivolumab and nivolumab in the treatment of resected melanoma

    The aim of this study is to test whether a new drug called ABP 206 (biosimilar nivolumab) works as well as the approved cancer drug OPDIVO® (nivolumab) in people with advanced cutaneous melanoma that has been surgically removed. The study divided people into 3 groups: one group will receive ABP 206, the second will receive real OPDIVO® approved in the US, and the third will receive the version of OPDIVO® approved in Europe. All of these medicines will be given through an intravenous drip every 4 weeks for up to 1 year, or until the cancer comes back or gets significantly worse.

    The main goal is to check whether ABP 206 (biosimilar nivolumab) is absorbed and maintained in the body in the same way as OPDIVO®. Researchers will also closely monitor how well it works, what the side effects are, and whether the body produces antibodies against it. The entire study will last approximately 13 months for each person joining.

    • Nivolumab biosimilar
    • Nivolumab
  • Study of DYP688 in patients with metastatic uveal melanoma

    The aim of this study is to test a new drug combination to treat metastatic uveal melanoma, a type of cancer that starts in the eye and spreads to other parts of the body. The main drugs being tested are IDE196 (also called darovasertib) and crizotinib, both taken by mouth twice daily.

    Currently, this process is divided into several stages. In the first part, investigators will test two different doses of IDE196 in combination with crizotinib and compare them to other approved therapies such as pembrolizumab, ipilimumab + nivolumab, or dacarbazine. Once they determine the best dose of IDE196, they will move to the next step in which everyone will receive that dose along with crizotinib or one of the other treatments.

    Researchers will primarily look at how long the cancer stays under control without getting worse and how long patients live. It could take about 4 years to get all the answers you need.

    • Darovasertib/IDE196
    • Dacarbazine
    • Nivolumab
    • Crizotinib
    • Ipilimumab
    • Pembrolizumab
  • Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    • Tebentafusp
    • Pembrolizumab
  • To evaluate the effectiveness of nivolumab used alone and in combination with HBI-8000 in the treatment of unresectable or metastatic melanoma

    This is a study comparing two treatment options for patients with melanoma that cannot be surgically removed or has spread to other parts of the body. One treatment option is an investigational drug called Tucidinostat (HBI-8000) taken by mouth twice a week in combination with an approved drug called nivolumab given by intravenous infusion. Another option is a placebo taken orally twice a week, also in combination with nivolumab given by intravenous infusion.

    The primary goal of the study is to determine whether the combination of HBI-8000 and nivolumab is more effective than nivolumab alone in shrinking the tumor or preventing further tumor progression. The study will also assess the safety of the treatment combinations.

    Patients enrolled in the main study will be randomly assigned to receive either the HBI-8000 combination or a placebo combination. Treatment will continue for up to 2 years or until the cancer progresses, side effects worsen or the patient decides to withdraw from the study. The study will last up to 4 years and will include regular monitoring and follow-up visits.

    • Placebo
    • Tudicdinostat/HBI-8000
  • Safety and efficacy of pembrolizumab in combination with investigational drugs in the first-line treatment of patients with melanoma

    The aim of this study is to test new experimental treatments for melanoma, which is a type of skin cancer. The main goal is to test whether these new treatments are safe and effective when used alone or in combination with the drug pembrolizumab.

    The current study includes several different treatment groups. Some groups receive pembrolizumab in combination with other investigational drugs such as vibostolimab, quavonlimab, lenvatinib, favezelimab, or Tretynoina (ATRA). Other groups simply receive pembrolizumab alone.

    Scientists will carefully look at factors such as dose-limiting toxicities and adverse events to make sure the treatment is safe. They will also check the effectiveness of the therapy by measuring, for example, the objective response rate, which shows whether tumors are shrinking or disappearing.

    • Tretynoina
    • Vibostolimab
    • Quavonlimab
    • Favezelimab
    • Pembrolizumab
    • Lenvatinib
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Acalabrutinib
    • Cyclophosphamide
    • Rituximab
  • Comparing new and standard treatments for non-small cell lung cancer

    This clinical trial compares novel treatment regimens against the standard of care in people with advanced non-small cell lung cancer (NSCLC). It’s divided into two parts: the first part focuses on safety and early response of new treatments. The second part compares the effectiveness and safety of these novel treatments with standard therapy. The trial includes drugs like docetaxel, feladilimab, ipilimumab, and others, evaluating their impact on cancer progression and patient survival. This study is significant for those seeking alternative treatments for advanced NSCLC.

    • Belrestotug
    • Feladilimab
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Ipilimumab
    • Docetaxel
  • Testing selinexor for relapsed large B-Cell lymphoma

    This clinical trial is about testing a drug called Selinexor on patients who have a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL) that has returned or hasn’t responded to treatment. Lymphoma is a type of cancer that starts in cells that are part of the body’s immune system. The trial is divided into two parts. In Part 1, the researchers will give 130 patients a 60mg dose of this drug to see how they respond. These patients have no other treatment options. In Part 2, the researchers will divide about 110 patients into two groups. One group will receive a 40mg dose and the other a 60mg dose. All the patients will be closely monitored until their disease progresses. The results of the study will be based on international guidelines and standards for assessing lymphoma.

    • Selinexor
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    • BNT113
    • Pembrolizumab
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Study on Aticaprant’s safety and effects as an adjunctive therapy for major depressive disorder

    This trial is for adults and elders who are struggling with major depressive disorder (MDD). The trial involves a medicine called aticaprant, and this is supposed to be taken alongside what they are already using to handle their depression (SSRI or SNRI drugs). The study aims to determine the long-term safety and efficacy of aticaprant. To achieve this, close monitoring of adverse events, which includes negative reactions or changes in patients’ health, is crucial. Physical health indicators, such as weight, core body temperature, heart rate, and blood pressure, will be assessed to understand the potential impact of aticaprant. Additionally, the study will evaluate patients’ thoughts on suicide, any discernible changes in their sexual health, and their overall mood.

    • Aticaprant
  • Study on customized therapy for advanced solid tumors

    The research study, now in its second phase, aims to examine if particular treatments, or treatment combinations, are safe and useful in treating certain hard-to-remove or spreading tumors. These treatments are personalized, chosen depending on certain genetic changes detected in a person’s tumor. It will take about 4 weeks to see if the treatment is successful. As part of the study, patients will have to answer some questions about their physical, emotional, mental, and social health, which will help paint a clear picture of their overall quality of life. Lastly, any negative impacts causes by the treatment are taken note of and classified according to their severity.

    • Divarasib/GDC-6036
    • Ipatasertib
    • Idasanutlin
    • Belvarafenib
    • Camonsertib
    • Pralsetinib
    • Entrectinib
    • Alectinib
    • Atezolizumab
    • Inavolisib
    • Trastuzumab Emtansine
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    • Magrolimab
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Zimberelimab
    • 5-Fluorouracil
    • Docetaxel

See more clinical trials in other cities in Italy:

.